Hematologic Oncology Update
Hematologic Oncology Update
✓

Chronic Lymphocytic Leukemia — Microlearning Activity 2

· show notes
00:27:51
Podcasts
RSS
Link

ABOUT THIS EPISODE

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

  • Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
  • Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)
  • Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)
  • Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)

CME information and select publications

Science
Medicine
English
United States
Use API to fetch this episode in JSON

SHOW NOTES 🔗

00:00:00Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
00:10:42Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL
00:15:50Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation
00:22:51Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673)

TRANSCRIPT 🔗

Are you the producer of this podcast? Add a podcast transcript
Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

SEARCH PAST EPISODES

Search past episodes of Hematologic Oncology Update.
Embed this search bar to your website

OTHER EPISODES IN THIS PODCAST

Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program

Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program

Featuring perspectives from Dr William G Wierda, including the following topics: Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00) Sequencing Road Map (12:39) Key Datasets — Pirtobrutinib (21:08) Investigator Survey (34:09) Chimeric Antigen Receptor T-Cell T…
00:58:40
SHARE
SAVE
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation a…
00:30:54
SHARE
SAVE
Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov

Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov

Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives…
00:49:41
SHARE
SAVE
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Featuring perspectives from Prof John Seymour, including the following topics: Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00) Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21) First-line treatment with sonrotocl…
00:22:58
SHARE
SAVE
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus

Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), …
00:59:49
SHARE
SAVE
Disclaimer: The podcast and artwork embedded on this page are from Dr. Neil Love, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
PROMOTED
We’re selling some of our podcast-related domain names, including breaker.fm, Podcast.mov, and Listen.Host. Place your bid on eBay.
We’re selling some of our podcast-related domain names, including breaker.fm, Podcast.mov, and Listen.Host. Place your bid on eBay.
Bid on eBay

RECOMMENDATIONS
Use API to fetch this episode